cropped-APGC22__logomark_cmyk.png
2024 Manila, Philippines
  • 00Days
  • 00Hrs
  • 00Mins
  • 00Secs
Alcon

Platinum Partner

Alcon

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning more than seven decades, we offer the broadest portfolio of products to enhance sight and improve people’s lives. 

Thursday 4 August 2022
1830-1930 GMT+8
Virtual

Introducing Hydrus® Microstent Into your Clinical Practice

Virtual industry symposium

Join us as we hear clinical trial outcomes and real-life experience on the latest microinvasive glaucoma surgery (MIGS) device by international experts.

Chelvin Sng

Introduction and Opening Remarks

Moderator: A/Prof Chelvin Sng
Chelvin Sng Eye Centre, Singapore

Dr Chelvin C. A. Sng is a Fellow of the Royal College of Surgeons of Edinburgh and has more than 15 years of experience in Ophthalmology. She graduated from Gonville and Caius College in Cambridge University with triple First Class Honours and Distinctions. As recipient of the Academic Medicine and Development Award, Dr Sng completed the prestigious glaucoma fellowship at Moorfields Eye Hospital in London, the largest eye hospital in Europe. During her fellowship, she was trained in the management of complex and severe glaucoma under the supervision of internationally renowned ophthalmologists, including Professor Keith Barton and Professor Sir Peng Khaw. After her fellowship, she was an Honorary Consultant at Moorfields Eye Hospital from 2015 to 2018.

Read More

Being the earliest Asian surgeon to implant several minimally invasive glaucoma surgery (MIGS) devices, Dr Sng is regarded as a pioneer of MIGS in Asia. She was appointed the Convenor of the Asia-Pacific Glaucoma Society (APGS)-MIGS Interest Group (https://apglaucomasociety.org/migs). Dr Sng is the co-inventor of the Paul Glaucoma Implant, and is also proficient in conventional glaucoma surgery (trabeculectomy, Ahmed glaucoma drainage device insertion and Baerveldt glaucoma drainage device insertion). Dr Sng is trained in complex cataract surgery, including the scleral fixation of intraocular lenses and femtosecond laser cataract surgery (bladeless cataract surgery).

Dr Sng is actively involved in research on glaucoma surgery and imaging, with over 70 publications in peer-reviewed journals.

Dr-G-Lee-photo

Hydrus® Outcomes in the 5 year HORIZON Trial

Dr Graham Lee
City Eye Centre Ophthalmic Consultants, Australia

Professor Graham Lee is one of a few specialists in the world who have completed both corneal & external diseases (Moorfields Eye Hospital, London) and glaucoma fellowships (Birmingham and Midlands Eye Hospital, Birmingham). He works in private and public clinics (Mater and QCH) managing cataract, complex anterior segment, corneal transplantation and glaucoma drainage procedures.
Read MoreIn these positions, he has been involved with the selection and training of Ophthalmology registrars and previously held the position of Director of Qualifications & Education in Queensland. He has been recognised by the Royal Australian and New Zealand College of Ophthalmology as a trainer of excellence.  Clinical research is a passion, having published more than 120 peer-reviewed publications in international journals and book chapters in major texts. He has been the recipient of national and international awards, including the Australasian Cataract & Refractive Society Film Festival twice and the World Glaucoma Congress Film Festival in Vancouver. Graham has presented more than 200 lectures worldwide and has a special interest in developing countries including Cambodia, Laos, Vietnam and Nepal.  He has co-founded a website https://iop.vision to promote high quality in-depth teaching of ophthalmology.
shamira-perera-portrait

Hydrus® Microstent Surgical Implantation Steps

A/Prof Shamira Perera
Singapore National Eye Centre, Singapore

Associate Professor Shamira Perera qualified from University of London, with a BSc(Hons) First Class and MBBS(Hons), obtained in 1994 and 1997 respectively. He relocated to Singapore from England in 2008 after completing two fellowships, and is currently a Senior Consultant Ophthalmologist in the Glaucoma Department at Singapore National Eye Centre (SNEC) with an interest in novel surgeries and imaging. He has commercialized two devices for cataract surgery licensed to companies in India and Germany. Supported by competitive research grants totalling over S$1.5M as PI, his core work has yielded nine patents. Associate Professor Perera has been an invited lecturer for over 100 conferences, written five book chapters and 138 peer reviewed publications. His most recent role as the Deputy Director of the Medical Technology office for SingHealth seeks to promote this promising area to other specialties, now disbursing $6M of catalyst grant funding.

Read More

In 2015, whilst holding the position of Co-head, Bioengineering and Devices at Singapore Eye Research Institute (SERI), he formed part of a group that won a national engineering award – the IES- Prestigious Engineering award, and the AHIP-GEM Award, an award for innovation, in 2017. He was conferred the AAO and APAO achievement awards in 2015 and 2016 respectively in recognition of his research and clinical work. One of his passions is teaching. He has co-authored a Golden Apple award winning, free app module in conjunction with Touch Surgery (www.touchsurgery.com) to teach and test cataract surgery, garnering over 750,000 downloads. He was also awarded the Outstanding Faculty award in 2018 and Outstanding teacher/mentor award in 2010. In 2019 he received the “Gamechanger” award from SingHealth and was recognized by AECOM (ASEAN Economic Community Ophthalmology Meeting) with the Distinguished Service Award in 2018.

Dr Nathan Kerr_Profile Photo

Integrating into Practice with Hydrus®

Dr Nathan Kerr
Eye Surgery Associates, Australia

Dr Nathan Kerr is a Specialist Ophthalmologist and Associate with Eye Surgery Associates who specialises in cataract and glaucoma surgery, and the management of most ophthalmic conditions.

Dr Kerr completed a two-year glaucoma and optic nerve fellowship for which he was awarded a Doctorate of Medicine prior to commencing ophthalmology speciality training.  After becoming a Fellow of the Royal Australian and New Zealand College of Ophthalmologists (FRANZCO),  Dr Kerr went on to complete an additional two years of glaucoma subspeciality training.  His first year was at the Royal Victorian Eye & Ear Hospital in Melbourne, and the second, at the pre-eminent Moorfields Eye Hospital in London where he in trained in minimally invasive glaucoma surgery (MIGS) under the world-renowned surgeon Mr Keith Barton.

Read More

Dr Nathan Kerr is the first fellowship-trained minimally invasive glaucoma surgeon in Australia.  He uses the most advanced micro-incision surgery and revolutionary microscopic glaucoma implants to reduce or eliminate the need for glaucoma eye drops.  He is a co-editor of MIGS.org and has been invited to teach MIGS surgery in the United Kingdom, Switzerland, and France.

Moderated Q&A

Dr Chelvin Sng & Panel

Friday 5 August 2022
1730-1930 GMT+8
Hybrid (Live + Virtual)

Hybrid WetLab Featuring the Hydrus® Microstent

hybird wetlab

Join us for a Hybrid Hydrus Microstent WetLab special, both Live in Exhibition Hall 6B and virtual broadcast.

Facilitators

Dr Nathan Kerr_Profile Photo

Dr Nathan Kerr
Eye Surgery Associates, Australia

View profile

Dr Nathan Kerr is a Specialist Ophthalmologist and Associate with Eye Surgery Associates who specialises in cataract and glaucoma surgery, and the management of most ophthalmic conditions.

Dr Kerr completed a two-year glaucoma and optic nerve fellowship for which he was awarded a Doctorate of Medicine prior to commencing ophthalmology speciality training.  After becoming a Fellow of the Royal Australian and New Zealand College of Ophthalmologists (FRANZCO),  Dr Kerr went on to complete an additional two years of glaucoma subspeciality training.  His first year was at the Royal Victorian Eye & Ear Hospital in Melbourne, and the second, at the pre-eminent Moorfields Eye Hospital in London where he in trained in minimally invasive glaucoma surgery (MIGS) under the world-renowned surgeon Mr Keith Barton.

Dr Nathan Kerr is the first fellowship-trained minimally invasive glaucoma surgeon in Australia.  He uses the most advanced micro-incision surgery and revolutionary microscopic glaucoma implants to reduce or eliminate the need for glaucoma eye drops.  He is a co-editor of MIGS.org and has been invited to teach MIGS surgery in the United Kingdom, Switzerland, and France.

shamira-perera-portrait

A/Prof Shamira Perera
Singapore National Eye Centre, Singapore

View profile

Associate Professor Shamira Perera qualified from University of London, with a BSc(Hons) First Class and MBBS(Hons), obtained in 1994 and 1997 respectively. He relocated to Singapore from England in 2008 after completing two fellowships, and is currently a Senior Consultant Ophthalmologist in the Glaucoma Department at Singapore National Eye Centre (SNEC) with an interest in novel surgeries and imaging. He has commercialized two devices for cataract surgery licensed to companies in India and Germany. Supported by competitive research grants totalling over S$1.5M as PI, his core work has yielded nine patents. Associate Professor Perera has been an invited lecturer for over 100 conferences, written five book chapters and 138 peer reviewed publications. His most recent role as the Deputy Director of the Medical Technology office for SingHealth seeks to promote this promising area to other specialties, now disbursing $6M of catalyst grant funding.

In 2015, whilst holding the position of Co-head, Bioengineering and Devices at Singapore Eye Research Institute (SERI), he formed part of a group that won a national engineering award – the IES- Prestigious Engineering award, and the AHIP-GEM Award, an award for innovation, in 2017. He was conferred the AAO and APAO achievement awards in 2015 and 2016 respectively in recognition of his research and clinical work. One of his passions is teaching. He has co-authored a Golden Apple award winning, free app module in conjunction with Touch Surgery (www.touchsurgery.com) to teach and test cataract surgery, garnering over 750,000 downloads. He was also awarded the Outstanding Faculty award in 2018 and Outstanding teacher/mentor award in 2010. In 2019 he received the “Gamechanger” award from SingHealth and was recognized by AECOM (ASEAN Economic Community Ophthalmology Meeting) with the Distinguished Service Award in 2018.

Bryan Ang

Dr Bryan Ang
Tan Tock Seng Hospital

View profile Dr Bryan Ang is a Consultant with the Glaucoma Service at the National Healthcare Group (NHG) Eye Institute @ Tan Tock Seng Hospital, Singapore. Dr Ang completed his undergraduate studies at the National University of Singapore (NUS), where he graduated on the Dean’s List for multiple academic years, was awarded a Distinction in Surgery and recognized as the 2nd Best Candidate in Surgery in his cohort. He further obtained his Masters in Medicine (Ophthalmology) from NUS, receiving the Gold Medal as the best candidate in the examinations. Upon completion of his specialist training, Dr Ang was elected as a Fellow of both the Royal College of Ophthalmologists (London) in 2016 and the Academy of Medicine Singapore in 2017. In 2017, Dr Ang served as Deputy Chief Resident at the NHG Eye Institute @ Tan Tock Seng Hospital. Dr Ang sub-specializes in Glaucoma and Cataract Surgery. His work in glaucoma surgery and surgical techniques, particularly in Minimally Invasive Glaucoma Surgery, have been recognized internationally, winning prestigious awards such as the 2nd Best Surgical Film Award at the World Glaucoma Congress 2019 and the Best Video Award at the American Academy of Ophthalmology (AAO) Annual Meeting 2021. Dr Ang is a regular speaker and instructor at regional and international conferences, including the Asia-Pacific Glaucoma Congress, AAO Annual Meeting and the World Ophthalmology Congress. Dr Ang is active in both teaching and research. He has published more than 25 scientific papers in international journals and previously won the NHG Eye Institute research prizes for the Best Paper Presentation (Intermediate Category) in 2014 and the Runner-Up Best Poster Award (Open Category) in 2018. Dr Ang is passionate about delivering quality clinical care. In 2014, Dr Ang was awarded the Singapore Health Quality Service Award (Silver) for outstanding clinical service. He is currently the Department Quality Reporting Officer for the NHG Eye Institute @ Tan Tock Seng Hospital.
Session agenda
1730
In-Person WetLab Session
delivery mode: in person only
Hydrus® Instructors
1830
WetLab Virtual Broadcast
delivery mode: in person and virtual broadcasting
Introductory Video
1835
Didactic Session & Hands-On WetLab

This includes Hydrus® Microstent surgical implantation steps didactic teaching with interactive discussion and WetLab with simulated eyes.
delivery mode: in person and virtual broadcasting
Dr Nathan Kerr

A/Prof Shamira Perera

Dr Bryan Ang
2000
Close
Alcon

Alcon

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning more than seven decades, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 20,000 associates are enhancing the quality of life through innovative products, partnerships with eye care professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.

Iridex

Iridex

At Iridex, we are redefining the glaucoma treatment paradigm with a versatile range of non-incisional, laser-based therapies: MicroPulse Laser Trabeculoplasty, MicroPulse Transscleral Laser Therapy, and Continuous-Wave Transscleral Cyclophotocoagulation. These therapies
provide physicians safe, effective, and versatile treatment options for a wide variety of glaucoma types and severities, to significantly reduce intraocular pressure and slow the progression of vision loss. More than 200,000 patients have been treated since 2015 with MicroPulse® TLT using the MicroPulse P3® Delivery Device. Visit iridex.com/webinars to learn how ophthalmologists and patients benefit from our non-incisional glaucoma procedures.

Kalson

Kalson Surgical

Bayer

Bayer Co. (Malaysia) Sdn Bhd

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. For more information, go to www.bayer.com.

DKSH_500x500

DKSH

DKSH is the leading growth partner for pharmaceutical companies in Asia. Our experts provide a range of integrated Market Expansion Services across the entire value chain, ranging from registration through to marketing, promotion and distribution.
Our capillary network reaches more than 130,000 hospitals, clinics, pharmacies, doctors and drugstores in Asia. Products are transported, stored and distributed efficiently thanks to our unmatched capacities and expertise in the region. Our solid infrastructure and dedication to compliance and quality reduce business risks for our partners.
We are committed to delivering the results you need to be successful. That’s why we continuously invest in our sales and marketing organization, which is fully embedded in our operations. Our teams work with clear measurements, activity-driven KPIs and standardized brand planning processes across the region. They are supported by regional Sales and Marketing Excellence and Business Development teams, allowing us to duplicate success across markets.
Headquartered and publicly listed in Switzerland, our local experts provide services to pharmaceutical companies in 13 Asian markets.

Glaukos Aventisin 500x500

Glaukos Corporation / Aventisin

Founded in 1998, Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.

We were the first company to bring to market Micro-Invasive Glaucoma Surgery (MIGS), the micro-invasive procedure that revolutionized the treatment and management of glaucoma. In 2012, we launched our first MIGS device—the iStent®—in the United States, followed by our next-generation iStent inject® device in September 2018 and iStent inject® W in September 2020.

In November 2019, Glaukos acquired Avedro, maker of the first and only FDA-approved cross-linking technology for progressive keratoconus. And we continue to seek to leverage our platform technologies to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies for
glaucoma, corneal health, and retinal diseases.

Our company completed an initial public offering in June of 2015, and our shares are traded on the New York Stock Exchange under the ticker symbol “GKOS”. Our global headquarters is located in Aliso Viejo, California, and we have additional locations in 9 regions around the world.

TRB

TRB Chemedica Malaysia

A subsidiary company of TRB CHEMEDICA INTERNATIONAL SA (Switzerland) established for almost 34 years in Malaysia, specialising in the use of hyaluronic acid in ophthalmology, rheumatology and orthopaedic for the management of ocular dryness, osteoarthritis and tendinopathy.

Nova Eye

Nova Eye Medical

With a legacy that spans more than 30 years in ophthalmology, Nova Eye Medical designs, develops, manufactures and markets a portfolio of proprietary glaucoma treatment technologies. Underpinning each of these technologies is our commitment to advance clinical outcomes and improve patient quality of life.

icare

Icare

iCare is a trusted partner in ophthalmic diagnostics, offering physicians fast, easy-to-use, and reliable tools for diagnosis of glaucoma, diabetic retinopathy, and macular degeneration (AMD).
Our devices cover automated fundus imaging systems, perimeters, and handheld rebound tonometers. iCare Solutions provide digital clinical tools that drive greater efficiency and enhance quality in eye care.
We believe that ophthalmic care must be accessible, effortless, and reliable, and our aim is to establish the next level of eye care.

Santen

Santen

As a specialized company dedicated to ophthalmology, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and devices. Santen is the market leader for prescription ophthalmic pharmaceuticals in Japan and its products now reach patients in over 60 countries. With scientific knowledge and organizational capabilities nurtured over a 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society. For more information, please visit https://www.santen.asia/

placeholder.png

Speaker Name

Sponsor bio – Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

placeholder.png

Sponsor Name

Sponsor bio – Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Contact